Mario Otto, MD, PhD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Mario Otto is an associate professor in the Division of Pediatric Hematology, Oncology and Bone Marrow Transplant at the University of Wisconsin School of Medicine and Public Health. He earned his medical degree from the University of Tuebingen School of Medicine, Germany and completed his residency at Children’s University Hospital, Tuebingen, Germany and Akron Children’s Hospital, Akron, OH. Dr. Otto is board certified in pediatrics and pediatric hematology/oncology and completed a fellowship at St. Jude Children’s Research Hospital, Memphis, TN.
He focuses his research on pursuing novel, alternative approaches to treat childhood cancer. His research includes areas such as adoptive immunotherapies, nano-oncology, stem cell graft design for haploidentical transplants, and the use of novel targeted radionuclides to treat pediatric malignancies.
Specialties
Clinics
UW School of Medicine and Public Health
| Department of Pediatrics |
Professional Certifications and Education
| Board Certification |
Pediatrics
Pediatric Hematology-Oncology |
| Fellowship |
St. Jude Children's Research Hospital, Memphis, TN
|
| Residency |
Children's University Hospital, Tuebingen, Germany
Akron Children's Hospital, Akron, OH |
| Internship |
Children's University Hospital, Tuebingen, Germany
|
| Medical School |
University of Tuebingen School of Medicine, Germany
|
Languages Spoken
| German |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
| Research |
Dr. Otto is pursuing novel, alternative approaches to treat childhood cancer. His research includes areas such as adoptive immunotherapies, nano-oncology and stem cell graft design for the transplant setting. |
PubMed Articles
-
Hall LT Titz B Baidya N van der Kolk AG Robins HI Otto M Perlman SB Weichert JP Kuo JS
[<sup>124</sup>I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors. Mol Imaging Biol . 2020 Apr;22(2):434-443
[PubMed ID: 31183841]
-
Marsh IR Grudzinski J Baiu DC Besemer A Hernandez R Jeffery JJ Weichert JP Otto M Bednarz BP
Preclinical Pharmacokinetics and Dosimetry Studies of <sup>124</sup>I/<sup>131</sup>I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models. J Nucl Med . 2019 Oct;60(10):1414-1420
[PubMed ID: 30926646]
-
Sahasrabudhe K Otto M Hematti P Kenkre V
TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data. Leuk Lymphoma . 2019 Mar;60(3):598-609
[PubMed ID: 30187806]
-
Elsaid MY Shahi A Wang AR Baiu DC Li C Werner LR Singhal S Hall LT Weichert JP Armstrong EA Bednarz BP Harari PM Iyer G Otto M
Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Mol Cancer Ther . 2018 Nov;17(11):2320-2328
[PubMed ID: 30108133]
-
Bednarz B Grudzinski J Marsh I Besemer A Baiu D Weichert J Otto M
Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents. Health Phys . 2018 Apr;114(4):450-459
[PubMed ID: 29481536]
-
Baiu DC Marsh IR Boruch AE Shahi A Bhattacharya S Jeffery JJ Zhao Q Hall LT Weichert JP Bednarz BP Otto M
Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog. J Nucl Med . 2018 Feb;59(2):244-250
[PubMed ID: 28747518]
-
Jiao P Otto M Geng Q Li C Li F Butch ER Snyder SE Zhou H Yan B
Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. J Mater Chem B . 2016 Jan 20;4(3):513-520
[PubMed ID: 27087966]
-
Marino R Baiu DC Bhattacharya S Titz B Hebron E Menapace BD Singhal S Eickhoff JC Asimakopoulos F Weichert JP Otto M
Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma. Am J Cancer Res . 2015;5(11):3422-35
[PubMed ID: 26807322]
-
Baiu DC Artz NS McElreath MR Menapace BD Hernando D Reeder SB Grüttner C Otto M
High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine (Lond) . 2015 Oct;10(19):2973-2988
[PubMed ID: 26420448]
-
McDowell KA Hank JA DeSantes KB Capitini CM Otto M Sondel PM
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol . 2015 Mar;37(2):79-93
[PubMed ID: 25590232]
-
Xu Y Baiu DC Sherwood JA McElreath MR Qin Y Lackey KH Otto M Bao Y
Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles. J Mater Chem B . 2014 Oct 7;2(37):6198-6206
[PubMed ID: 26660881]
-
Navid F Sondel PM Barfield R Shulkin BL Kaufman RA Allay JA Gan J Hutson P Seo S Kim K Goldberg J Hank JA Billups CA Wu J Furman WL McGregor LM Otto M Gillies SD Handgretinger R Santana VM
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol . 2014 May 10;32(14):1445-52
[PubMed ID: 24711551]
-
Capitini CM Otto M DeSantes KB Sondel PM
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol . 2014;10(9):1659-78
[PubMed ID: 25145434]
-
Baiu DC Brazel CS Bao Y Otto M
Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology. Curr Pharm Des . 2013;19(37):6606-21
[PubMed ID: 23621531]
-
Otto M Shulkin BL Kundu M Sandlund JT Snyder SE Metzger ML
Histiocyte-rich xanthomatous pseudotumor mimicking relapse on positron emission tomography imaging in an adolescent with primary mediastinal diffuse large B-cell lymphoma. J Pediatr Hematol Oncol . 2012 Apr;34(3):232-5
[PubMed ID: 22082744]
-
Jiao P Zhou H Otto M Mu Q Li L Su G Zhang Y Butch ER Snyder SE Jiang G Yan B
Leading neuroblastoma cells to die by multiple premeditated attacks from a multifunctionalized nanoconstruct. J Am Chem Soc . 2011 Sep 7;133(35):13918-21
[PubMed ID: 21827210]
-
Sorkin LS Otto M Baldwin WM 3rd Vail E Gillies SD Handgretinger R Barfield RC Ming Yu H Yu AL
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain . 2010 Apr;149(1):135-42
[PubMed ID: 20171010]
-
Barfield R Chen X Otto M Handgretinger R
Beyond the FACS. Stem Cells . 2007 Nov;25(11):2972
[PubMed ID: 17656640]
-
Otto M Chen X Martin WJ Leung W Knowles J Holladay M Houston J Handgretinger R Barfield RC
Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells . 2007 Feb;25(2):537-42
[PubMed ID: 17023516]
-
Otto M Barfield RC Martin WJ Iyengar R Leung W Leimig T Chaleff S Gillies SD Handgretinger R
Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res . 2005 Dec 1;11(23):8486-91
[PubMed ID: 16322312]